Goldman Sachs upgrades Rocket Pharmaceuticals to Neutral and raises price target to $4
Goldman Sachs lifted its rating on Rocket Pharmaceuticals from Sell to Neutral and increased its price target from $3 to $4. The upgrade was prompted by the company's recent update on RP‑A501 for Danon disease, which included long‑term Phase 1 data indicating lasting disease improvement and early Phase 2 efficacy signals. Rocket also secured a $150 million credit facility to fund operations into Q3 2028. Goldman noted the drug’s commercial upside but remained cautious about the $1 billion‑$2 billion peak‑sales outlook.
Why it matters
The higher rating and price target suggest a more favorable view of Rocket’s clinical progress, which could support the stock price if the trial proceeds as planned. Goldman’s caution signals that investors should weigh the commercial potential against the uncertainty of achieving the projected peak sales.
Key facts
- 1Goldman Sachs changed its rating on Rocket Pharmaceuticals from Sell to Neutral. tipranks.com
- 2Goldman raised its price target for Rocket Pharmaceuticals from $3.00 to $4.00. tipranks.com
- 3Rocket reported long‑term Phase 1 data showing disease improvement or stabilization for up to seven years after treatment. investing.com
- 4Preliminary efficacy was observed in the first four Phase 2 patients treated at a recalibrated dose. investing.com
- 5Rocket secured a credit facility with Hercules for up to $150 million, expected to fund operations into the third quarter of 2028. investing.com
- 6The company guided potential global peak sales of $1 billion to $2 billion for the initial indication. tipranks.com
Summary written by AlphAI from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.